We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Miniature Device to Transform Testing of Blood Cancer Treatments

By LabMedica International staff writers
Posted on 02 Jul 2025

Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for blood cancers like leukemia, offering hope to patients when other treatments fail. More...

However, despite its promise, nearly half of leukemia patients relapse, and many suffer from serious side effects. Efforts to improve CAR T therapies have been hampered by the limitations of conventional testing methods. Traditional models fail to accurately replicate the complex human immune response and the bone marrow environment where leukemia develops. Now, researchers have developed a new solution to bridge this gap—a platform that allows for real-time observation of cancer treatment interactions under controlled conditions, offering a more accurate and patient-specific approach to testing blood cancer therapies.

This innovative platform, termed “leukemia-on-a-chip,” was developed through a collaboration between the Perelman School of Medicine at the University of Pennsylvania (Philadelphia, PA, USA) and the Tandon School of Engineering at New York University (Brooklyn, NY, USA). The device is the first to successfully recreate the physical and immunological environment of human bone marrow on a microscope slide-sized chip. It integrates three distinct bone marrow regions—blood vessels, surrounding marrow cavity, and the outer bone lining—and when seeded with patient-derived cells, it self-organizes to produce structural proteins such as collagen, fibronectin, and laminin. Importantly, the device preserves the immune cell activity within the marrow microenvironment. The system incorporates vascular networks to simulate realistic immune interactions in three dimensions, providing a level of insight and accuracy far beyond 2D cultures or animal models. The development is also timely, coinciding with the FDA’s new roadmap to reduce animal testing requirements in drug development.

In their study published in Nature Biomedical Engineering, the researchers used advanced imaging to watch CAR T cells move through blood vessels, detect cancer cells, and destroy them—processes previously impossible to view with this clarity. They observed that engineered immune cells not only targeted leukemia cells but also activated other immune cells nearby in a “bystander effect” that may explain both therapeutic success and some side effects. The team simulated different patient responses, including remission, relapse, and resistance, and demonstrated that newer, fourth-generation CAR T cells performed better than standard versions, even at lower doses. The chip setup takes just half a day to assemble and supports experiments for up to two weeks, in contrast to animal models that require months. Going forward, the researchers aim to use this platform to test individual patient cancer cells against various treatment designs, enabling a personalized approach to therapy selection before treatment begins.

Related Links:
Perelman School of Medicine
Tandon School of Engineering


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.